AUSTRALASIA

We supply a diversified portfolio of branded prescription, OTC and consumer health products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semi-solids.

Key Countries

Australia
New Zealand

Contribution to Group revenue (%)

Revenue by segment (%)

The Australian pharmaceutical sector was valued at USD12,3 billion as at 30 December 2018
Aspen was ranked 3rd by volume in the Australian pharmaceutical sector for the 12 months ended 31 August 2019
Almost one in seven scripts written in Australia is for a product distributed by Aspen
Aspen’s overall sales representation performance rankings MAT March 2019 shows continued improvement and a sustained number one position

Source: June 2019 IQVIA

STATISTICS

Number of products launched:

4

(2018: 3)^#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

USD85 million

3 – 5 years

USD17 million

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover*:

9,9%

(2018: 13,0%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

^# The number of product launches has been restated to take into account discontinued operations.
^ Includes 49 employees transferred with the disposal of the Nutritionals business.
* Rate excludes employees transferred in Nutritionals disposal.

Revenue	2019 R'million	2018 (CER) R'million	Change %
Regional Brands	3 363	3 218	5
Sterile Focus Brands	685	750	(9)
Anaesthetics Brands	663	729	(9)
Thrombosis Brands	22	21	5
Total Commercial Pharmaceuticals	4 048	3 968	2
Manufacturing – FDF	372	367	1
Total	4 420	4 335	2

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography and manufacturing revenue by place of manufacture.